GlassScriptPhysician profile
Brian James Nagle
NPI 1346745890
$25,173.47
in general payments reported to CMS, 2019-2025
23 companies · $99.32 in 2025
The $99.32 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.91 · 2020: $133 · 2021: $105 · 2022: $22K · 2023: $2,097 · 2024: $259 · 2025: $99.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,768 · Consulting Fee: $642 · Education: $45.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,768.16 |
| Consulting Fee | $642.00 |
| Education | $45.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $20,995.17 | 2022 | |
| Amneal Pharmaceuticals LLC | $954.23 | 2019-2023 | Rytary, Lyvispah |
| Abbvie INC. | $746.25 | 2022-2023 | |
| Acadia Pharmaceuticals INC | $720.86 | 2021-2023 | Nuplazid |
| Amgen INC. | $258.89 | 2024 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $195.18 | 2023 | Austedo, Austedo Xr |
| Merz Pharmaceuticals, LLC | $186.72 | 2022-2023 | Xeomin |
| Abbott Laboratories | $172.37 | 2023 | Infinity |
| Merz North America, INC. | $132.74 | 2020 | |
| Mdd US Operations, LLC | $125.38 | 2022-2023 | Gocovri |
| Kyowa Kirin, INC. | $123.46 | 2021-2023 | Nourianz |
| Argenx US, INC. | $99.32 | 2025 | Vyvgart Hytrulo |
| Acorda Therapeutics, INC | $77.72 | 2022-2023 | Inbrija, Ampyra |
| Boston Scientific Corporation | $69.01 | 2022-2023 | |
| Supernus Pharmaceuticals, INC. | $65.13 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $55.37 | 2022 | |
| Lilly USA, LLC | $47.62 | 2022 | |
| Allergan, INC. | $41.52 | 2019-2021 | |
| Corium, LLC | $34.96 | 2023 | Adlarity |
| Otsuka America Pharmaceutical, INC. | $20.90 | 2023 | Nuedexta |
| Avion Pharmaceuticals | $20.39 | 2023 | Dhivy |
| Azurity Pharmaceuticals, INC. | $18.28 | 2023 | Horizant |
| Ipsen Biopharmaceuticals, INC | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Nagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.